
Drug deals dominated much of the international relations between biotech companies. But now, another change: the way China’s biotech companies structure their innovation shows a major shift, known widely as “NewCo,” says long-term China lawyer Mark Schaub on the website of his law firm, King&Wood.
Mark Schaub:
Perhaps the biggest development in China biotech dealmaking right now isn’t a drug but a new way of structuring deals.
Known widely as “NewCo” this model involves a Chinese biotech licensing out the international rights to one or more drug pipelines/candidates to a newly formed offshore company funded by foreign investors.
In most cases the NewCo is run by an international management team with the plan of a future IPO or trade sale to a pharma company. The model has rapidly gained traction in 2025/2026.
The beauty of this structure is that it solves three problems at once: 1) Chinese parent retains a stake in the international economic upside of its assets; 2) foreign investors have a clean, ring-fenced platform to fund and operate without being involved in the Chinese parent’s broader local operations; and 3) allows parties to have a clearer financing and exit path than an open-ended joint venture.
The NewCo solves the dilemma of Chinese innovators and Western capital wishing to work together to globalise Chinese-developed drugs without foreign funders being overly involved in the China business where their added value may be limited. The Chinese innovator can continue developing and commercialising the product in China, where it already has management capability, clinical infrastructure and access to domestic funding. The foreign investors can concentrate their capital and expertise on their strength which is international development.
Although clever, the structure depends on careful and creative drafting – the parties will need to agree on governance rights, IP carve-outs, IP improvements, milestone triggers, and exit mechanics. These cannot be left to be worked out later – by its nature the parties’ interests will diverge along with the technology. In many cases the Chinese and Western products may look very different over time despite sharing a common ancestor. Like the VIE structure before it, the NewCo structure can solve a lot of problems but if it is not set up and implemented properly it can also lead to a lot of problems.
Mark Schaub is a speaker at the China Speakers Bureau. Do you need him at your meeting or conference? Do get in touch or fill in our speakers’ request form.
Are you looking for more strategic experts at the China Speakers Bureau? Do check out this list.





